In CRC, NSUN2 exerts its oncogenic effects through the NSUN2/YBX1/m5C-ENO1 signaling axis, providing a rationale for combining NSUN2 inhibitors in CRC treatment (190). Here, ENO1 is linked to colorectal carcinoma.